transwell inserts culture membrane  (Corning Life Sciences)

Journal: Communications Biology

Article Title: HBV DNA integration gene CCDC91 is oncogenic and a potential therapeutic target for hepatocellular carcinoma

doi: 10.1038/s42003-025-08369-1

Figure Lengend Snippet: A The mRNA level of CCDC91 in CCDC91-overexpressing HCC cells and control cells revealed by qPCR (n = 3). B The protein level of CCDC91 in CCDC91-overexpressing HCC cells and control cells detected by western blot. C Cell proliferation of CCDC91-overexpressing HCC cells and control cells detected by CCK8 assay (n = 3). D , E The migration abilities of CCDC91-overexpressing HCC cells and control cells measured by wound healing assay (n = 3). The migration ( F ) and invasion ( G ) abilities of CCDC91-overexpressing HCC cells and control cells measured by transwell assay (n = 3). H Cell proliferation of CCDC91 knockdown HCC cells and control cells detected by CCK8 assay (n = 3). I , J The migration abilities of CCDC91 knockdown HCC cells and control cells measured by wound healing assay (n = 3). K , L The migration and invasion abilities of CCDC91 knockdown HCC cells and control cells measured by transwell assay (n = 3). Statistical analysis was performed using Student’s t test in ( A , C , E , F , G , H , J , and L ). Data represents mean ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001.

Article Snippet: Cell migration or invasion was measured using Transwell inserts with an 8 μm pore size culture membrane (Corning, Ithaca, NY, USA) covered without or with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) before use.

Techniques: Control, Western Blot, CCK-8 Assay, Migration, Wound Healing Assay, Transwell Assay, Knockdown

Journal: Communications Biology

Article Title: HBV DNA integration gene CCDC91 is oncogenic and a potential therapeutic target for hepatocellular carcinoma

doi: 10.1038/s42003-025-08369-1

Figure Lengend Snippet: A Co-IP with antibody against CCDC91 followed by Western blot in HepG2 and PLC/PRF/5 cells (n = 3). B Immunofluorescence staining of CCDC91 and LDHA in CCDC91-overexpressing HCC cells and control cells. C The mRNA level of LDHA in CCDC91-overexpressing HCC cells with or without LDHA knockdown revealed by qPCR (n = 3). D The protein level of LDHA in CCDC91-overexpressing HCC cells with or without LDHA knockdown detected by western blot (n = 3). E Cell proliferation of CCDC91-overexpressing HCC cells with or without LDHA knockdown detected by CCK8 assay (n = 3). ( F – I ). F , G The migration abilities of CCDC91-overexpressing HCC cells with or without LDHA knockdown measured by transwell assay (n = 3). The migration ( H , I ) and invasion ( J , K ) abilities of CCDC91-overexpressing HCC cells with or without LDHA knockdown measured by wound healing and transwell assay, respectively (n = 3). L Glucose levels were detected in CCDC91-overexpressing HCC cells with or without LDHA knockdown (n = 3). M Lactate levels were detected in CCDC91-overexpressing HCC cells with or without LDHA knockdown (n = 3). Statistical analysis was performed using Student’s t test in ( C , E , G , I , K , L , and M ). Data represents mean ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001.

Article Snippet: Cell migration or invasion was measured using Transwell inserts with an 8 μm pore size culture membrane (Corning, Ithaca, NY, USA) covered without or with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) before use.

Techniques: Co-Immunoprecipitation Assay, Western Blot, Immunofluorescence, Staining, Control, Knockdown, CCK-8 Assay, Migration, Transwell Assay

Journal: Communications Biology

Article Title: HBV DNA integration gene CCDC91 is oncogenic and a potential therapeutic target for hepatocellular carcinoma

doi: 10.1038/s42003-025-08369-1

Figure Lengend Snippet: A The Kaplan–Meier analysis revealed the association of CCDC91 with the progression free survival of HCC patients that treated with sorafenib from TMA cohort (n = 77). B The Kaplan–Meier analysis revealed the association of CCDC91 with the overall survival of HCC patients that treated with sorafenib from TMA cohort (n = 80). C Cell proliferation of CCDC91-overexpressing HCC cells and control cells with or without sorafenib detected by CCK8 assay for 24 h, 48 h and 72 h separately (n = 3). The migration ( D ) and invasion ( E ) abilities of CCDC91-overexpressing HCC cells with or without sorafenib measured by transwell assay for 18 h (n = 3). F – H Huh-7 cells stably expressing SC or shCCDC91 were injected subcutaneously into the flanks of nude mice administrated without or with sorafenib (n = 5). Representative images of dissected tumors at the end of the experiment were shown. G Tumor growth curves of mice during sorafenib treatment were analyzed (n = 5). And xenografts were weighted (n = 5, H ). All control cells were treated with an equivalent volume of DMSO to account for potential solvent effects, while the experimental groups were treated with sorafenib dissolved in DMSO. Statistical analysis was performed using Student’s t test in ( C , D , E , and H ). Two-way ANOVA was used for tumor volume in G Data represents mean ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001.

Article Snippet: Cell migration or invasion was measured using Transwell inserts with an 8 μm pore size culture membrane (Corning, Ithaca, NY, USA) covered without or with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) before use.

Techniques: Control, CCK-8 Assay, Migration, Transwell Assay, Stable Transfection, Expressing, Injection, Solvent

Journal: Communications Biology

Article Title: HBV DNA integration gene CCDC91 is oncogenic and a potential therapeutic target for hepatocellular carcinoma

doi: 10.1038/s42003-025-08369-1

Figure Lengend Snippet: A The protein level of HBx in HepG2 and PLC/PRF/5 cells with or without Ct-HBx transfection detected by western blot (n = 3). B The mRNA level of CCDC91 in HepG2 cells with or without Ct-HBx transfection revealed by qPCR (n = 3). C Co-IP with antibody against HBx followed by Western blot in HepG2 and PLC/PRF/5 cells (n = 3). D Immunofluorescence staining of CCDC91 and HBx in HepG2 and PLC/PRF/5 cells with or without Ct-HBx transfection. E Cell proliferation of HepG2 and PLC/PRF/5 cells with or without Ct-HBx transfection detected by CCK8 assay (n = 3). F , G ) The migration and invasion abilities of HepG2 and PLC/PRF/5 cells with or without Ct-HBx transfection measured by transwell assay (n = 3). H The protein level of HBx, CCDC91, and LDHA in HepG2 and PLC/PRF/5 cells with or without Ct-HBx transfection revealed by western blot (n = 3). I Schematic diagram illustrating the proposed mechanisms of the effects of the HBV-integrated gene CCDC91 on HCC. Statistical analysis was performed using Student’s t test in ( B , E , F , and G ). Data represents mean ± SEM.*, p < 0.05; **, p < 0.01; ***, p < 0.001.

Article Snippet: Cell migration or invasion was measured using Transwell inserts with an 8 μm pore size culture membrane (Corning, Ithaca, NY, USA) covered without or with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) before use.

Techniques: Transfection, Western Blot, Co-Immunoprecipitation Assay, Immunofluorescence, Staining, CCK-8 Assay, Migration, Transwell Assay